The FDA granted accelerated approval to the anti-PD-1 monoclonal antibody pembrolizumab in 2017 as third line treatment for patients with recurrent, locally advanced or metastatic PD-L1-positive GC/GEJC (Fuchs et al., 2018). The gene discussed is CD274; the disease is gastric cancer.